Practice Variation in Perioperative Dexamethasone Use and Outcomes in Brain Metastasis Resection
JAMA Network Open · 11.04.2025 · 8 (4) · e254689
DOI: 10.1001/jamanetworkopen.2025.4689 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Network Open, online erschienen am 11.04.2025. Verfasst von David Wasilewski und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berl…. Hauptthemen laut MEDLINE: Dexamethasone, Brain Neoplasms, Perioperative Care. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Variations in perioperative dexamethasone dosing are common in brain metastasis resection, but their impact on patient outcomes remains unclear.
Objective
To evaluate the association between perioperative dexamethasone dosing and patient outcomes, focusing on overall survival (OS) and progression-free survival (PFS). Design, Setting, and Participants This retrospective multicenter comparative effectiveness study used data collected from January 2010 to December 2023. Patients with symptomatic brain metastases undergoing primary surgical resection at 7 neurological centers in Germany and 1 in Austria and who had complete records of perioperative dexamethasone dosing were included. Propensity score matching (PSM) was used to control for confounders. Analysis was conducted from March to June 2024. Exposures Cumulative perioperative dexamethasone administration over 27 days, dichotomized at 122 mg using maximally selected rank statistics. Main Outcomes and Measures The primary outcome was OS. Secondary outcomes included extracranial PFS (ecPFS) and intracranial PFS (icPFS) as well as incidence of wound revision surgery after brain metastasis resection. Hazard ratios (HRs) were calculated using Cox proportional hazards models.
Results
A total of 1064 patients were included in the analysis. The median (IQR) age was 64 (56-72) years, with 489 female patients (49%) and 541 male patients (51%). Non–small cell lung cancer (NSCLC) was the most common tumor entity (564 patients [53%]), followed by breast cancer (146 patients [14%]) and melanoma (138 patients [13%]). After PSM, patients receiving cumulative dexamethasone doses less than 122 mg had a median OS of 19.1 (95% CI, 15.2-22.4) months compared with 12.0 (95% CI, 9.1-14.7) months for those receiving 122 mg or more ( P = .002). Multivariable analysis showed an independent association between higher cumulative dexamethasone doses and reduced OS (HR, 1.40; 95% CI, 1.18-1.66; P < .001). Secondary analyses demonstrated consistent findings with icPFS and ecPFS and a dose-response association between cumulative dexamethasone and hazard for death. Conclusions and Relevance In this study, higher cumulative perioperative dexamethasone was associated with reduced OS, icPFS, and ecPFS in patients undergoing brain metastasis resection. These findings suggest that stricter dosing protocols could improve outcomes. Prospective trials are warranted to confirm these associations and guide evidence-based practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Charité Comprehensive Cancer Center, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Department of Neurosurgery, University Regensburg Medical Center, Regensburg, Germany.
- Wilhelm-Sander Neuro-Oncology Unit, University Regensburg Medical Center, Regensburg, Germany.
- Department of Neurosurgery, University Medicine Rostock, Rostock, Germany.
Zitieren
APA
Wasilewski, D., Araceli, T., Rafaelian, A., Demetz, M., Asey, B., Ersoy, T. F., Dauth, A., Neumeister, A., Peukert, R., Pöser, P., Krämer, C., Bukatz, J., Shaked, Z., Jelgersma, C., Früh, A., Xu, R., Misch, M., Capper, D., Ehret, F., …, & Onken, J. (2025). Practice Variation in Perioperative Dexamethasone Use and Outcomes in Brain Metastasis Resection. JAMA Network Open, 8(4), e254689. https://doi.org/10.1001/jamanetworkopen.2025.4689
Vancouver
Wasilewski D, Araceli T, Rafaelian A, Demetz M, Asey B, Ersoy TF, et al. Practice Variation in Perioperative Dexamethasone Use and Outcomes in Brain Metastasis Resection. JAMA Network Open. 2025;8(4):e254689. doi:10.1001/jamanetworkopen.2025.4689
BibTeX
@article{Wasilewski2025,
author = {Wasilewski, David and Araceli, Tommaso and Rafaelian, Artem and Demetz, Matthias and Asey, Benedikt and Ersoy, Tunc-Faik and Dauth, Alice and Neumeister, Anne and Peukert, Ricarda and Pöser, Paul and Krämer, Christopher and Bukatz, Jan and Shaked, Zoe and Jelgersma, Claudius and Früh, Anton and Xu, Ran and Misch, Martin and Capper, David and Ehret, Felix and Frost, Nikolaj and Bullinger, Lars and Keilholz, Ulrich and Senft, Christian and Schmidt, Leon and Krenzlin, Harald and Ringel, Florian and Pohrt, Anne and Meyer, Hanno S and Gempt, Jens and Kerschbaumer, Johannes and Freyschlag, Christian and Thomé, Claudius and Simon, Matthias and Dubinski, Daniel and Freiman, Thomas and Schmidt, Nils Ole and Proescholdt, Martin and Vajkoczy, Peter and Onken, Julia},
title = {Practice Variation in Perioperative Dexamethasone Use and Outcomes in Brain Metastasis Resection},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {4},
pages = {e254689},
doi = {10.1001/jamanetworkopen.2025.4689}
}
EUVIMED